Status:

COMPLETED

A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community

Lead Sponsor:

Jiangxi University of Traditional Chinese Medicine

Conditions:

Primary Hypertension

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Heat-sensitive moxibustion, an important mean of external therapy of traditional Chinese medicine, has unique advantages in treating various chronic diseases than common moxibustion. This study aims t...

Detailed Description

Primary hypertension is a common chronic disease that threatens the life and health of human beings. The conventional western drug therapy often has side effects and many patients are unable to achiev...

Eligibility Criteria

Inclusion

  • Diagnosed with essential hypertension, i.e., systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90 mmHg, with a course more than 6 months.
  • Ages: 18-80 years;
  • The original antihypertensive drugs are calcium channel blockers and/or angiotensin II receptor blockers.
  • Did not receive acupoint stimulation therapies for hypertension in the last month.
  • Patients in the heat-sensitive moxibustion groups need to develop at least one type of moxibustion sensation around the following acupoints: Yongquan, Baihui, Shenque, Quchi, Zusanli, Hegu, Taichong and Dazhui.
  • Consent to sign an informed consent form

Exclusion

  • Systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg after taking antihypertensive drugs;
  • Secondary hypertension.
  • Pregnancy and lactation;
  • Allergic to moxibustion devices, moxa smoke or Artemisia argyi.
  • Complicated with severe diseases that are not recommended for heat-sensitive moxibustion, such as acute cerebral hemorrhage, hypertensive crisis, sensory disturbances, serious mental diseases, etc.

Key Trial Info

Start Date :

March 10 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 9 2021

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT04788563

Start Date

March 10 2021

End Date

December 9 2021

Last Update

July 3 2024

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Erliuling

Nanchang, Jiangxi, China, 330004

2

Hongmiao

Nanchang, Jiangxi, China, 330004

3

Jinghexinggong community

Nanchang, Jiangxi, China, 330004

4

Jinsheng community

Nanchang, Jiangxi, China, 330004